The Phase I clinical trial, known as BD-Ebov, will evaluate the safety of the experimental vaccine and its ability to stimulate immune responses in healthy adult volunteers.

The world's first clinical trial of a vaccine targeting the Bundibugyo strain of Ebola has begun, marking a milestone in efforts to contain the outbreak in central Africa.